{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"221"},{"groupId":"OG002","value":"225"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"221"},{"groupId":"OG002","value":"225"}],"units":"Participants"}],"description":"A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.","groups":[{"description":"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Part A: Ramucirumab + Erlotinib"},{"description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Part B: Ramucirumab + Erlotinib"},{"description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG002","title":"Part B: Placebo + Erlotinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 through End of Study (Up To 3 Years)","title":"Number of Participants With Treatment-Emergent Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}